Regulatory Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Pharmaceutical TechnologyBoehringer Ingelheim has received Japan's MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF.RespiratoryRead full story pharminent May 18, 2026 (Last updated: May 21, 2026) Pharmaceutical Technology Boehringer Ingelheim has received Japan’s MHLW approval for Jascayd (nerandomilast) to treat adults with IPF and PPF. Respiratory Read full story Post navigation Previous: Another LAG-3 setback as Regeneron drug fails phase 3 trialNext: Japan’s MHLW approves Boehringer’s Jascayd for IPF and PPF Related Stories Regulatory Scholar Rock’s muscle-targeting SMA therapy Isemblyd lands FDA approval pharminent September 14, 2026 Regulatory Psychedelic therapies ride wave of public favor into FDA hearing pharminent September 14, 2026 Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026